胶原蛋白改性聚乳酸-羟基乙酸载药纳米纤维膜的制备及其性能

为改善聚乳酸-羟基乙酸共聚物(PLGA)基药物载体的降解性能和释药性能,以PLGA为基材,以胶原蛋白(Col)为改性材料,以阿霉素(DOX)为药物模型,利用静电纺丝技术制备得到PLGA/Col/DOX纳米纤维膜,探究了胶原蛋白对其亲疏水性、体外降解性、释药性能及细胞相容性的影响。结果表明:PLGA与Col以3:1的质量比复合制得的纳米纤维膜性能最佳;经胶原蛋白复合改性后,纳米纤维膜的接触角由未改性的93.5°降至51.5°,亲水性显著提高;胶原蛋白改性可大幅提高PLGA的降解性,改性后纳米纤维膜30 d的质量损失速率由未改性的3.5%增加至19%,且改性后纳米载药纤维膜的药物释放速率和细胞相容性明显提高,有利于细胞黏附增殖。

Preparation and properties of modified poly(lactide-co-glycolide) nano-scaled drug delivery system by collagen

In order to improve the slow degradation rate of poly(lactic acid-glycolic acid copolymer) (PLGA) and improve the drug release performances of PLGA-based drug loading materials, collagen (Col) as the modified material and doxorubicin (DOX) as the drug model, PLGA/Col/DOX nanofibrous membranes were prepared by electrostatic spinning technology with PLGA as the substrate, which can be used as sustained-release material for local tumor treatment. Modification effect of collagen on the hydrophilicity-hydrophobicity, in-vitro degradation, drug release performance and cytocompatibility of PLGA-based drug delivery system was investigated. The results showed that the properties of PLGA/Col nanofibrous membranes with a mass ratio of 75/25 were the best. After modification by collagen, the contact angle of the nanofibrous membrane decreased from 93.5°to 51.5°, indicating significant improvement of hydrophilicity. In-vitro degradation experiments showed that the 30-day weight loss rates of the nanofibers before and after collagen modification were 3.5% and 19% respectively, suggesting that the addition of collagen could greatly improve the degradation of PLGA. In-vitro drug release experiments showed that the drug release rate was significantly increased after modification, which could effectively improve the defects of low drug release rate and low drug release amount of PLGA. Cytotoxicity experiments showed that collagen could improve the biocompatibility of PLGA and facilitate cell adhesion and proliferation.